1259 related articles for article (PubMed ID: 25891804)
1. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
2. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
7. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Nauck MA
Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
[TBL] [Abstract][Full Text] [Related]
8. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
10. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
[TBL] [Abstract][Full Text] [Related]
12. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
13. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
14. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Storgaard H; Gluud LL; Bennett C; Grøndahl MF; Christensen MB; Knop FK; Vilsbøll T
PLoS One; 2016; 11(11):e0166125. PubMed ID: 27835680
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Fioretto P; Giaccari A; Sesti G
Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
[TBL] [Abstract][Full Text] [Related]
16. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
17. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
[TBL] [Abstract][Full Text] [Related]
18. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
[TBL] [Abstract][Full Text] [Related]
19. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
20. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
